杜比實驗室 DLB 深 滬
已收盤 08-08 16:00:00 美东时间
72.56
+0.580
+0.81%
華盛通- 最 高73.07
- 今 開72.12
- 成交量 30.15万股
- 最 低 72.12
- 昨 收 71.98
- 總市值 69.71亿
- 52周最高 89.00
- 市盈率 靜 26.97
- 換手率 0.00%
- 52周最低 67.35
- 委 比 6.17%
- 總股本 9606.62万
- 歷史最高 100.03
- 量 比 0.58
- 振 幅 1.32%
- 歷史最低 16.83
- 每 手 1
- 風險率 4.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多百济神州港股公司深度研究：龙头Biopharma高举高打， 商业化和研发迎收获期
作者：甘坛焕、姜铸轩 摘要 ■投资逻辑 新一代Biopharma龙头，商业化与研发迎来关键拐点。公司高举高打，具有全球化的研产销一体...
08-07 07:36
被市场“忽略”的和黄医药，暗藏多个爆发点
（来源：药剂Talks） 今年以来，创新药行情迎来了大爆发。 从整体表现看，无论A股还是港股创新药企，2025年至今股价涨幅表现亮眼，大部分药企涨幅超过50...
08-05 18:27
Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and maintains $95 price target.
08-01 20:00
Dolby Laboratories declares $0.33 dividend
Dolby Laboratories, Inc. (NYSE:DLB) declares $0.33/share quarterly dividend, in line with previous. Forward yield 1.75% Payable Aug. 20; for shareholders of record Aug. 12; ex-div Aug. 12. The company...
08-01 16:57
【华鑫宏观策略】八月策略和十大金股
（来源：华鑫研究） ▌ 总量观点 核心要点：海外关注经济韧性、关税进展和9月降息预期。美股延续科技成长配置，左侧布局美债、黄金、美股中的地产、金融...
08-01 09:00
Dolby Laboratories Sees Q4 Adj EPS $0.61-$0.76 vs $0.77 Est; Sees Sales $288.000M-$318.000M vs $310.12M Est
Dolby Laboratories (NYSE:DLB) is looking for Q4 Adj EPS of $0.61-$0.76 vs $0.77 analyst estimate. sees sales of $288.000 million-$318.000 million vs $310.12 million analyst estimate.
08-01 04:17
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Dolby Laboratories, Inc. Q3 2025 Earnings Preview
Dolby Laboratories, Inc. (NYSE:DLB) is scheduled to announce Q3 earnings results on Thursday, July 31st, after market close. The consensus EPS Estimate is $0.71 (flat Y/Y) and the consensus Revenue Es...
07-31 00:49
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.
07-28 23:20
Lantern Pharma Reports Complete Metabolic Response In A Heavily Pre-Treated Lymphoma Patient With LP-284 In Its Phase 1 Clinical Trial
AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens.Complete response in an aggressive, recurring B-cell
07-23 19:58
